Bringans, S.; Peters, K.; Casey, T.; Ito, J.; Lipscombe, R.
The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease. Proteomes 2020, 8, 31.
https://doi.org/10.3390/proteomes8040031
AMA Style
Bringans S, Peters K, Casey T, Ito J, Lipscombe R.
The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease. Proteomes. 2020; 8(4):31.
https://doi.org/10.3390/proteomes8040031
Chicago/Turabian Style
Bringans, Scott, Kirsten Peters, Tammy Casey, Jason Ito, and Richard Lipscombe.
2020. "The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease" Proteomes 8, no. 4: 31.
https://doi.org/10.3390/proteomes8040031
APA Style
Bringans, S., Peters, K., Casey, T., Ito, J., & Lipscombe, R.
(2020). The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease. Proteomes, 8(4), 31.
https://doi.org/10.3390/proteomes8040031